ARPA-H Bets $125M on On-Demand, Personalized RNA Manufacturing
- ARPA-H is funding automated manufacturing systems to produce personalized RNA medicines near the point of care in under a week, awarding up to $125M across five teams under its GIVE program.
- The largest award, up to $54.5M, went to Waterfall Scientific, which leads a six-company consortium building a continuous-flow, cell-free mRNA manufacturing and characterization platform (project ESCALATOR).
- Consortium partners include Ansa Biotechnologies (enzymatic DNA synthesis), Volta Labs (automated fluid handling), Polymorphic Biosciences (LNP formulation), Tensentric (hardware engineering) and Ginkgo Bioworks.
- Goal: compress custom RNA drug production timelines from months to days, enabling distributed, patient-proximate manufacturing without sacrificing quality.
ARPA-H is capitalizing infrastructure here, not a specific drug — Waterfall's $54.5M award and the government's stamp of approval become leverage for the consortium's next fundraising or partnering conversations. Non-dilutive capital validating a shared-infrastructure model lowers the barrier for N-of-1 and other personalized RNA programs smaller biotechs could never justify building dedicated GMP capacity for. For Ansa, it validates enzymatic DNA synthesis as a manufacturing input beyond its core synbio pitch; for Ginkgo, it's another foundry contract reinforcing the picks-and-shovels positioning it's leaned on since COVID-testing revenue dried up. Washington is treating rapid, decentralized genetic-medicine manufacturing as a national-capability question now, not just a therapeutic one.